TARDBP and proteostasis deficiencies: In our results, ASO treatment led to a reduction in TDP‐43 pathology, which was accompanied by improved behavioural outcomes in VCP A232E mice, highlighting the therapeutic potential of reducing TDP‐43 dysregulation in multisystem proteinopathy.